Immune checkpoint inhibitors (ICI) act on co-inhibitory receptors, such as CTLA-4 and PD-1, on immune system cells, or their ligands, such as PD-L1, on tumor and immune cells, in order to prevent the resistance of these cells to the immune system, potentiating the cytotoxic killing of tumor cells [154]. This evidence concerns the gene CD274 and neoplasm.